Findings

What do systematic reviews say?

30 questions · 30 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 3 · 10%Very low 10 · 33.3%Low 12 · 40%Moderate 2 · 6.7%High 3 · 10%

SSRIs or SNRIs vs other antidepressants

Headache duration (hours) · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Low

SSRIs or SNRIs vs other antidepressants

Symptomatic/analgesic medication use for acute headache attacks · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Low

SSRIs or SNRIs vs other antidepressants

Headache index · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Very low

SSRIs or SNRIs vs other antidepressants

Quality of life · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

SSRIs or SNRIs vs other antidepressants

Withdrawals due to adverse events · patients with tension‐type headache

SSRIs or SNRIs showed no clear difference in withdrawals due to adverse events compared with other antidepressants (low certainty).

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
OR 1.04 [0.41, 2.6]
4 studies · 257 participants
Low

SSRIs or SNRIs vs other antidepressants

Headache (frequency) · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Very low

SSRIs or SNRIs vs other antidepressants

Headache intensity (mean score) · patients with tension‐type headache

1 finding from 1 review

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a continuous outcome · patients with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 237 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low